Pavilion GR41675 – Genentech - Roche [Enrollment Closed]
A Phase III, Multicenter, Randomized study of the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranizumab in patients with Diabetic Retinopathy
Condor: CRTH258D2301 – Novartis [Enrollment Closed]
Novartis pharmaceuticals trail entitled: A 96-week, two-arm, randomized single-masked, multi-center, Phase III study assessing the efficacy and safety of Brolucizumab 6mg compared to Panretinal Photocoagulation Laser in patients with Proliferative Diabetic Retinopathy.